Research programme: plasminogen activator inhibitor-1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Small molecules
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson